Vanda Pharmaceuticals Inc.

VNDA · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders6.6%

Institutions86.4%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$216.10M	$198.77M	$192.64M	$254.38M	$268.68M	$248.17M	$227.19M	$193.12M	$165.08M	$146.02M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	–	–	–	–	–	$24.49M	$20.51M	$17.85M	$24.71M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$151.17M	-$40.66M	-$13.95M	$6.33M	$42.16M	$27.24M	$22.81M	$21.74M	-$16.90M	-$18.57M
Operating income as a percentage of revenue.	-70.0%	-20.5%	-7.2%	2.5%	15.7%	11.0%	10.0%	11.3%	-10.2%	-12.7%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$220.47M	-$18.90M	$2.51M	$6.28M	$33.15M	$23.34M	$115.55M	$25.21M	-$15.57M	-$18.01M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.74	$-0.33	$0.04	$0.11	$0.60	$0.43	$2.17	$0.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.74	$-0.33	$0.04	$0.11	$0.58	$0.42	$2.11	$0.00	$0.00	$0.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$84.85M	$102.32M	$135.82M	$135.03M	$52.07M	$61.03M	$45.07M	$61.01M	$33.63M	$40.43M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$488.95M	$656.20M	$648.44M	$634.25M	$593.79M	$533.46M	$483.75M	$332.13M	$205.43M	$210.37M
Everything the company owes — debt, unpaid bills, and other obligations.	$161.76M	$117.66M	$103.53M	$107.05M	$88.86M	$80.19M	$72.80M	$56.71M	$74.04M	$79.04M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$327.19M	$538.55M	$544.91M	$527.20M	$504.93M	$453.27M	$410.94M	$275.42M	$131.39M	$131.33M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$109.44M	-$15.76M	$12.80M	$31.98M	$64.21M	$51.77M	$45.95M	$29.99M	-$1.98M	-$8.10M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$998000	$490000	$383000	$679000	$552000	$1.79M	$1.02M	$368000	$1.66M	$1.41M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$110.44M	-$16.25M	$12.42M	$31.30M	$63.66M	$49.98M	$44.93M	$29.62M	-$3.65M	-$9.51M

	You	Peer avg
Revenue Growth	-3.9%	+66.3%
ROE	-77.8%	-76.0%

Vanda Pharmaceuticals Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison